Khaled Musallam/LinkedIn
Sep 28, 2025, 08:41
Khaled Musallam Explores Molecular Understanding of β-Thalassemia at The 2nd Abu Dhabi Hematology Annual Review
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Great program and talks during the 2nd Abu Dhabi Hematology Annual Review.
Thanks Dr Kayane Mheidly and Sheikh Shakhbout Medical City – SSMC for giving the stage to thalassemia.”
Stay updated with Hemostasis Today.
-
Mar 1, 2026, 05:44Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?